Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PCS 499

Drug Profile

PCS 499

Alternative Names: CTP-499; PCS-499

Latest Information Update: 02 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Concert Pharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Organic deuterium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Antioxidants; Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Necrobiosis lipoidica
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Necrobiosis lipoidica
  • Discontinued Diabetic nephropathies; Kidney disorders

Most Recent Events

  • 26 Apr 2019 Concert Pharmaceuticals has patent protection for PCS 499 in USA, Europe, Australia, Canada, China, Japan, Mexico, Taiwan, Hong Kong, Russia, South Korea, the Philippines and South Africa
  • 01 Mar 2019 Pharmacokinetics and adverse events data from a phase I trial in Necrobiosis lipoidica (in volunteers) presented at the 77th Annual Meeting of the American Academy of Dermatology (AAD-2019)
  • 07 Nov 2018 Phase-II clinical trials in Necrobiosis lipoidica in USA (PO) (NCT03698864)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top